Support us
Michiel de Maaker

Michiel de Maaker

Technician

Phone Email Marleen Kok Core Facility Molecular Pathology & Biobanking

In March 2017 I started as technician to work on the TONIC trial. This study investigates the effect and effectiveness of treatment with the new drug nivolumab (immunotherapy). The new drug is administered after a low dose of radiation or chemotherapy. I also continued my work with the Young Boost Trial.

The main objective of theYoung Boost trial is to compare the effect of a high boost dose (26 Gy) with a low boost dose (16 Gy) in breast conserving therapy, on the local recurrence rate.

Additional objectives are:

To test the genotypic and phenotypic profiles of breast tumors in young patients with invasive breast cancer, and its relation  to:

a. Local recurrence after breast conserving treatment
b. Lymph node metastases
c. Distant metastases and survival
d. Radio sensitivity
e. Age


Fields of expertise

Molecular biology

Work experience

2016-2017
AMC
Library prep IonTorrent

2012-2016
Antoni van Leeuwenhoek Hospital
Project: the Young Boost stud and PAPBI (Preoperative Accelerated Partial Breast Irradiation) study

2011-2012
InteRNA
Project:  role of microRNAs in head and neck tumors.

2009-2011
Project:  role of microRNAs in head and neck tumors.

2006-2011
VU University Medical Center, Cancer Center Amsterdam

2006 – 2008
VU
Project: Research focuses on optimizing and validating new diagnostic methods for detecting small residue cancer cells in head and neck tumors using real time pcr.

2003-2006
Kreatech Biotechnology BV
Kreatech  developed a technology with which DNA, RNA and proteins can be labeled quickly and non-enzymatically (FISH probes)

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.